Pharmaceutical Industry
Forbes - Mar 26th, 2025
Which Side Will Makary Take In The Fight Over Weight Loss Drugs?
FDA's New Chief Faces Controversy Over Weight Loss Drug Compounding Battle
Benzinga - Dec 18th, 2024
Pharmacy Benefit Managers Played Key Role in Worsening Opioid Crisis, Drug Makers Paid Staggering Rebates To Middlemen: NYT
Pharmacy benefit managers (PBMs) – key intermediaries in the U.S. pharmaceutical supply chain – have come under scrutiny for their role in exacerbating the opioid epidemic.While presenting themselves as proactive in curbing opioid abuse, PBMs quietly profited from arrangements with drugmakers that undermined safeguards against overprescribing, a recent investigation by The New York Times reveals.The three largest PBMs—UnitedHealth Group Inc. (NYSE:UNH), through its Optum unit, CVS Health Corp. (NYSE:CVS) via CVS Caremark, and Cigna Corp. (NYSE:CI) through Express Scripts oversee prescription drug access for over 200 million Americans.Several state and local governments have filed lawsuits against drug companies and PBMs, accusing them of inflating insulin prices.These companies negotiate drug prices on behalf of insurers and employers, often collecting rebates from manufacturers in exchange for favorable placement on insurance formularies.However, the NYT report says that internal documents reveal that PBMs repeatedly bargained away restrictions that could have curbed opioid misuse in exchange for lucrative rebates.For example, Purdue Pharma, the maker ...Full story available on Benzinga.com
Showing 1 to 2 of 2 results